Cargando…

Cardiovascular disease in SARS‐CoV‐2 infection

Pre‐existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID‐19 and is strongly associated with poor disease outcomes. However, SARS‐CoV‐2 infection can also trigger de novo acute and chronic cardiovascular disease. Acute cardiac complications include arrhythmia, myocardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Kei, Sinclair, Jane E, Sadeghirad, Habib, Fraser, John F, Short, Kirsty R, Kulasinghe, Arutha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423130/
https://www.ncbi.nlm.nih.gov/pubmed/34512975
http://dx.doi.org/10.1002/cti2.1343
_version_ 1783749401644105728
author Sato, Kei
Sinclair, Jane E
Sadeghirad, Habib
Fraser, John F
Short, Kirsty R
Kulasinghe, Arutha
author_facet Sato, Kei
Sinclair, Jane E
Sadeghirad, Habib
Fraser, John F
Short, Kirsty R
Kulasinghe, Arutha
author_sort Sato, Kei
collection PubMed
description Pre‐existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID‐19 and is strongly associated with poor disease outcomes. However, SARS‐CoV‐2 infection can also trigger de novo acute and chronic cardiovascular disease. Acute cardiac complications include arrhythmia, myocarditis and heart failure, which are significantly associated with higher in‐hospital mortality. The possible mechanisms by which SARS‐CoV‐2 causes this acute cardiac disease include direct damage caused by viral invasion of cardiomyocytes as well as indirect damage through systemic inflammation. The long‐term cardiac complications associated with COVID‐19 are incompletely characterised and thought to include hypertension, arrhythmia, coronary atherosclerosis and heart failure. Although some cardiac‐related symptoms can last over 6 months, the effect of these complications on long‐term patient health remains unclear. The risk factors associated with long‐term cardiovascular disease remain poorly defined. Determining which patients are most at‐risk of long‐term cardiovascular disease is vital so that targeted follow‐up and patient care can be provided. The aim of this review was to summarise the current evidence of the acute and long‐term cardiovascular consequences of SARS‐CoV‐2 infection and the mechanisms by which SARS‐CoV‐2 may cause cardiovascular disease.
format Online
Article
Text
id pubmed-8423130
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84231302021-09-10 Cardiovascular disease in SARS‐CoV‐2 infection Sato, Kei Sinclair, Jane E Sadeghirad, Habib Fraser, John F Short, Kirsty R Kulasinghe, Arutha Clin Transl Immunology Special Feature Review Pre‐existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID‐19 and is strongly associated with poor disease outcomes. However, SARS‐CoV‐2 infection can also trigger de novo acute and chronic cardiovascular disease. Acute cardiac complications include arrhythmia, myocarditis and heart failure, which are significantly associated with higher in‐hospital mortality. The possible mechanisms by which SARS‐CoV‐2 causes this acute cardiac disease include direct damage caused by viral invasion of cardiomyocytes as well as indirect damage through systemic inflammation. The long‐term cardiac complications associated with COVID‐19 are incompletely characterised and thought to include hypertension, arrhythmia, coronary atherosclerosis and heart failure. Although some cardiac‐related symptoms can last over 6 months, the effect of these complications on long‐term patient health remains unclear. The risk factors associated with long‐term cardiovascular disease remain poorly defined. Determining which patients are most at‐risk of long‐term cardiovascular disease is vital so that targeted follow‐up and patient care can be provided. The aim of this review was to summarise the current evidence of the acute and long‐term cardiovascular consequences of SARS‐CoV‐2 infection and the mechanisms by which SARS‐CoV‐2 may cause cardiovascular disease. John Wiley and Sons Inc. 2021-09-07 /pmc/articles/PMC8423130/ /pubmed/34512975 http://dx.doi.org/10.1002/cti2.1343 Text en © 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Special Feature Review
Sato, Kei
Sinclair, Jane E
Sadeghirad, Habib
Fraser, John F
Short, Kirsty R
Kulasinghe, Arutha
Cardiovascular disease in SARS‐CoV‐2 infection
title Cardiovascular disease in SARS‐CoV‐2 infection
title_full Cardiovascular disease in SARS‐CoV‐2 infection
title_fullStr Cardiovascular disease in SARS‐CoV‐2 infection
title_full_unstemmed Cardiovascular disease in SARS‐CoV‐2 infection
title_short Cardiovascular disease in SARS‐CoV‐2 infection
title_sort cardiovascular disease in sars‐cov‐2 infection
topic Special Feature Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423130/
https://www.ncbi.nlm.nih.gov/pubmed/34512975
http://dx.doi.org/10.1002/cti2.1343
work_keys_str_mv AT satokei cardiovasculardiseaseinsarscov2infection
AT sinclairjanee cardiovasculardiseaseinsarscov2infection
AT sadeghiradhabib cardiovasculardiseaseinsarscov2infection
AT fraserjohnf cardiovasculardiseaseinsarscov2infection
AT shortkirstyr cardiovasculardiseaseinsarscov2infection
AT kulasinghearutha cardiovasculardiseaseinsarscov2infection